Sleep apnea is the indication that survives when weight loss does not
There is exactly one thing on a GLP-1 label that is not a weight claim and not a diabetes claim, and it turns out to be the most valuable sentence on the page. Tirzepatide is approved to treat moderate to severe obstructive sleep apnea in adults with obesity, on the strength of two trials that measured breathing events per hour. Where a payer excludes weight-loss agents as a class, an indication that is not a weight-loss indication is a different question.
What this comes down to
- SURMOUNT-OSA ran two trials of 52 weeks: one in people not using positive airway pressure and one in people who were. The primary endpoint was change in the apnea-hypopnea index.
- Mean apnea-hypopnea index fell by 25.3 events per hour with tirzepatide against 5.3 with placebo in the first trial, and by 29.3 against 5.5 in the second.
- The approved tirzepatide label carries the indication in its own bullet: to treat moderate to severe obstructive sleep apnea in adults with obesity. The approved semaglutide label does not.
- At least one state Medicaid program that removed the drug from its weight-loss list kept a prior-authorization route open specifically for obstructive sleep apnea.
What the trial measured
SURMOUNT-OSA was run as two parallel trials in adults with moderate-to-severe obstructive sleep apnea and obesity, split by whether the participant was using positive airway pressure at baseline. Both randomized one-to-one to the maximum tolerated dose of tirzepatide or placebo for 52 weeks, with the change in the apnea-hypopnea index as the primary endpoint. Mean baseline apnea-hypopnea index was 51.5 events per hour in the first trial and 49.5 in the second, and mean body-mass index was 39.1 and 38.7[1].
| Trial | Tirzepatide | Placebo | Estimated difference |
|---|---|---|---|
| Trial 1, no positive airway pressure | -25.3 per hour | -5.3 per hour | -20.0 per hour |
| Trial 2, on positive airway pressure | -29.3 per hour | -5.5 per hour | -23.8 per hour |
SURMOUNT-OSA, change in apnea-hypopnea index at week 52
Both differences were reported with a P value below 0.001, and the trial reports significant improvements in every prespecified key secondary endpoint, including hypoxic burden, high-sensitivity C-reactive protein, systolic blood pressure and patient-reported sleep outcomes. The most frequent adverse events were gastrointestinal and mostly mild to moderate, which is the same sentence the head-to-head trial wrote about the same drug.
Body weight fell in both arms of this trial too, and the sleep benefit travels with it. That does not make the indication a trick — the trial measured breathing events and reported breathing events — but it does mean a reader deciding between drugs on this basis is not choosing between a weight mechanism and a different one.
Only one label carries it
The approved tirzepatide weight product lists two indications, and the second is to treat moderate to severe obstructive sleep apnea in adults with obesity[2]. The approved semaglutide product's indications are cardiovascular risk reduction, weight reduction and maintenance, and noncirrhotic steatohepatitis with moderate to advanced fibrosis[3]. Sleep apnea is not among them. That is a real difference between two drugs that get sold as substitutes, and it is one of the few places where which molecule you are prescribed changes what a payer is being asked to pay for.
PubMed, via the E-utilities API
(tirzepatide[tiab] OR semaglutide[tiab]) AND ("obstructive sleep apnea"[tiab] OR "sleep apnoea"[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]Returned 6. Positive control — semaglutide, identical trial filter with no sleep term — returned 316 through the identical filter in the same session.
Six records, and reading the list by relevance shows most of them are secondary and post hoc work on the same two SURMOUNT-OSA trials — patient-reported outcomes, time course, cardiometabolic secondary outcomes — rather than independent trials. One program generates a literature. The control is there because a filter that matched nothing would look identical to a field with no trials in it.
Why this is a coverage article as much as a trial article
A payer that excludes agents used for weight loss has excluded a use, not a molecule. That is why the indication matters. California's program took three drugs off its contract list effective January 1, 2026 and kept one route open: prior authorization, considered case by case, for obstructive sleep apnea. How the rest of the state map looks is its own page, and the pattern there is that the surviving routes are almost always indications rather than exceptions. It is worth knowing how thin the surrounding literature is before treating this as a settled second use: six randomized-trial records carry both these drugs and an obstructive sleep apnea term, and most are secondary reports on the same two trials[4].
For a cash buyer the calculation is different but the fact is the same: a diagnosis that is not obesity changes who the prescription belongs to. Nobody on this site holds a license to tell you whether you have sleep apnea. What we can tell you is that the label distinguishes between the two indications, that only one product carries the second one, and that prior authorization turns on exactly that kind of distinction.
Questions people actually ask
Is a GLP-1 approved for sleep apnea?
Tirzepatide is. The approved tirzepatide weight product carries an indication to treat moderate to severe obstructive sleep apnea in adults with obesity. No approved semaglutide product carries that indication.
How much did the trial improve sleep apnea?
In participants not using positive airway pressure, mean apnea-hypopnea index fell by 25.3 events per hour with tirzepatide against 5.3 with placebo over 52 weeks. In participants already using positive airway pressure, the falls were 29.3 and 5.5 events per hour.
Does it replace a CPAP machine?
The trial did not test that. One of its two arms enrolled people who were already using positive airway pressure and kept them on it, so what was measured was the drug added to that therapy rather than substituted for it.
Can the sleep apnea indication get a prescription covered?
Sometimes, and it is the route most likely to survive a weight-loss exclusion, because the exclusion is written about a use rather than a drug. At least one state program we documented removed the drugs from its weight-loss list and kept a case-by-case prior authorization route open for obstructive sleep apnea.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine, 2024. PMID 38912654 · doi:10.1056/NEJMoa2404881Two 52-week trials in adults with moderate-to-severe obstructive sleep apnea and obesity, split by baseline positive airway pressure use, randomized one-to-one to maximum tolerated tirzepatide (10 mg or 15 mg) or placebo. Mean baseline apnea-hypopnea index was 51.5 and 49.5 events per hour and mean BMI 39.1 and 38.7. Mean change in AHI at week 52 was -25.3 versus -5.3 events per hour in trial 1 (estimated difference -20.0, P<0.001) and -29.3 versus -5.5 in trial 2 (estimated difference -23.8, P<0.001), with significant improvements in all prespecified key secondary endpoints and gastrointestinal events most frequent.
- 2.ZEPBOUND (tirzepatide) injection — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated August 2026The indications section of the SPL with effective time 20260828 lists, as a separate bullet, treatment of moderate to severe obstructive sleep apnea in adults with obesity, alongside reduction and long-term maintenance of excess body weight.
- 3.WEGOVY (semaglutide) injection and tablets — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated June 2026The indications section of the SPL with effective time 20260618 lists cardiovascular risk reduction, weight reduction and long-term maintenance, and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. Obstructive sleep apnea is not among them.
- 4.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-12, tirzepatide or semaglutide with an obstructive sleep apnea term through the randomized-trial and human-indexing filter returned 6, against 316 for semaglutide through the identical filter with no sleep term.
Key figures